(Q35144042)

6 August 2017

1 reference

title

Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease (English)

1 reference

6 August 2017

main subject

human papilloma virus

1 reference

human papillomavirus

29 September 2024

N Randall Chu

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

477-486

1 reference

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Sexually transmitted infection as a cause of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Prophylactic and therapeutic vaccines for genital papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The role of human papillomavirus vaccines in cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The treatment of human papillomavirus lesions of the lower genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Therapeutic Approaches to Genital Warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immunological events in regressing genital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immune evasion in human papillomavirus-associated cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Spinning molecular immunology into successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Cytotoxic T lymphocyte activation by cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immunological concepts of vaccine adjuvant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Papillomavirus-like particle based vaccines: cervical cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immune responses to stress proteins: applications to infectious disease and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

In vivo tracking of tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Prognostic factors and new therapeutic approaches to cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Activity of HspE7, a novel immunotherapy, in patients with anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

Immunity to oncogenic human papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.477

21 January 2018

Identifiers

DOI

10.1517/14712598.3.3.477

1 reference

6 August 2017

1 reference